X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SANOFI INDIA VENUS REMEDIES/
SANOFI INDIA
 
P/E (TTM) x -949.6 30.5 - View Chart
P/BV x 0.3 5.4 5.2% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 VENUS REMEDIES   SANOFI INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
SANOFI INDIA
Dec-16
VENUS REMEDIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2184,560 4.8%   
Low Rs824,400 1.9%   
Sales per share (Unadj.) Rs365.61,028.5 35.5%  
Earnings per share (Unadj.) Rs1.5129.0 1.2%  
Cash flow per share (Unadj.) Rs37.9186.0 20.4%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs382.5753.6 50.8%  
Shares outstanding (eoy) m11.4423.03 49.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.4 9.4%   
Avg P/E ratio x101.034.7 290.7%  
P/CF ratio (eoy) x4.024.1 16.4%  
Price / Book Value ratio x0.45.9 6.6%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m1,717103,174 1.7%   
No. of employees `0001.03.6 28.2%   
Total wages/salary Rs m3243,592 9.0%   
Avg. sales/employee Rs Th4,100.76,537.7 62.7%   
Avg. wages/employee Rs Th318.0991.4 32.1%   
Avg. net profit/employee Rs Th16.7819.8 2.0%   
INCOME DATA
Net Sales Rs m4,18323,686 17.7%  
Other income Rs m20708 2.8%   
Total revenues Rs m4,20324,394 17.2%   
Gross profit Rs m8125,281 15.4%  
Depreciation Rs m4171,313 31.7%   
Interest Rs m38015 2,532.0%   
Profit before tax Rs m354,661 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m181,691 1.1%   
Profit after tax Rs m172,970 0.6%  
Gross profit margin %19.422.3 87.0%  
Effective tax rate %51.636.3 142.1%   
Net profit margin %0.412.5 3.2%  
BALANCE SHEET DATA
Current assets Rs m2,77115,673 17.7%   
Current liabilities Rs m1,9316,678 28.9%   
Net working cap to sales %20.138.0 52.8%  
Current ratio x1.42.3 61.1%  
Inventory Days Days12576 164.6%  
Debtors Days Days5422 240.9%  
Net fixed assets Rs m5,3288,098 65.8%   
Share capital Rs m114230 49.7%   
"Free" reserves Rs m4,17717,088 24.4%   
Net worth Rs m4,37617,356 25.2%   
Long term debt Rs m1,9110-   
Total assets Rs m8,42825,400 33.2%  
Interest coverage x1.1311.7 0.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.9 53.2%   
Return on assets %4.711.8 40.1%  
Return on equity %0.417.1 2.3%  
Return on capital %6.626.9 24.5%  
Exports to sales %024.5 0.0%   
Imports to sales %20.528.0 73.3%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs m8586,627 13.0%   
Fx inflow Rs m07,145 0.0%   
Fx outflow Rs m8586,846 12.5%   
Net fx Rs m-858299 -287.1%   
CASH FLOW
From Operations Rs m4693,226 14.5%  
From Investments Rs m29-1,555 -1.9%  
From Financial Activity Rs m-464-1,818 25.5%  
Net Cashflow Rs m35-147 -23.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.2 14.4 1.3%  
FIIs % 0.6 14.6 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 15,184 132.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  MERCK LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Novartis India Rallies 7%(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement this week.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

The Recipe to Over 60% Returns in Less Than a Year(The 5 Minute Wrapup)

Sep 9, 2017

Short term crisis in some companies could unveil some great investing opportunities.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 21, 2017 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS